KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Operating Margin (2019 - 2025)

Historic Operating Margin for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to 62.44%.

  • Royalty Pharma's Operating Margin rose 15400.0% to 62.44% in Q4 2025 from the same period last year, while for Dec 2025 it was 65.58%, marking a year-over-year increase of 84800.0%. This contributed to the annual value of 65.58% for FY2025, which is 84800.0% up from last year.
  • Per Royalty Pharma's latest filing, its Operating Margin stood at 62.44% for Q4 2025, which was up 15400.0% from 70.11% recorded in Q3 2025.
  • Royalty Pharma's Operating Margin's 5-year high stood at 134.23% during Q2 2021, with a 5-year trough of 85.31% in Q4 2022.
  • Over the past 5 years, Royalty Pharma's median Operating Margin value was 50.96% (recorded in 2021), while the average stood at 52.44%.
  • Per our database at Business Quant, Royalty Pharma's Operating Margin plummeted by -1119600bps in 2022 and then skyrocketed by 1881400bps in 2023.
  • Quarter analysis of 5 years shows Royalty Pharma's Operating Margin stood at 26.65% in 2021, then plummeted by -420bps to 85.31% in 2022, then skyrocketed by 221bps to 102.82% in 2023, then tumbled by -41bps to 60.9% in 2024, then grew by 3bps to 62.44% in 2025.
  • Its Operating Margin stands at 62.44% for Q4 2025, versus 70.11% for Q3 2025 and 36.26% for Q2 2025.